{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:43:52Z","timestamp":1756572232481,"version":"3.41.0"},"reference-count":65,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Bullous pemphigoid (BP) is a chronic autoimmune blistering disease primarily affecting the elderly population. While awaiting the results from randomized clinical trials to assess the effect of dupilumab in patients with BP, clinicians have begun to introduce dupilumab into their therapeutic arsenal, with few data supporting their clinical decisions. The objectives were to assess time to disease control, predictors of response, achievement of disease control, disease recurrence, and occurrence of adverse events. Randomized and non-randomized studies of interventions (NRSIs) from Medline and Embase were reviewed. A total of 315 studies were identified and 5 NRSIs (167 participants with moderate-to-severe BP) meeting our inclusion criteria were found. Dupilumab was significantly associated with shorter time to disease control compared with the control group (HR 2.71\u00a0 [95% CI, 1.85\u20133.96; I2\u2009=\u200935%; 127 participants; 4 studies]). The overall strength of the evidence was graded as very low due to serious risk of bias and imprecision of effect measures. There were insufficient data to inform conclusions regarding BP recurrence and adverse events. Evidence was found that dupilumab reduces time to disease control in BP. It was not possible to assess predictors of response using pre-planned meta-regression. Randomized controlled trials are needed to determine dupilumab\u2019s place in therapeutic algorithms for BP.\nPROSPERO number: CRD42024599235<\/jats:p>","DOI":"10.2340\/actadv.v105.43667","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:58:42Z","timestamp":1748350722000},"page":"adv43667","source":"Crossref","is-referenced-by-count":1,"title":["Time to Disease Control with Dupilumab for Bullous Pemphigoid: A Systematic Review and Meta-analysis"],"prefix":"10.2340","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8026-5102","authenticated-orcid":false,"given":"Laurence","family":"Mainville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-4517","authenticated-orcid":false,"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7388-9475","authenticated-orcid":false,"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4637-2291","authenticated-orcid":false,"given":"David O.","family":"Croitoru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"112966","doi-asserted-by":"crossref","unstructured":"Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Subepithelial autoimmune blistering dermatoses: clinical features and diagnosis. J Am Acad Dermatol 2021; 85: 1\u201314.","DOI":"10.1016\/j.jaad.2020.11.076"},{"key":"112967","unstructured":"https:\/\/doi.org.com\/10.1016\/j.jaad.2020.11.076"},{"key":"112968","doi-asserted-by":"crossref","unstructured":"Persson MSM, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol 2022; 186: 414\u2013425.","DOI":"10.1111\/bjd.20743"},{"key":"112969","unstructured":"https:\/\/doi.org.com\/10.1111\/bjd.20743"},{"key":"112970","doi-asserted-by":"crossref","unstructured":"Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol 2001; 117: 1097\u20131102.","DOI":"10.1046\/j.0022-202x.2001.01505.x"},{"key":"112971","unstructured":"https:\/\/doi.org.com\/10.1046\/j.0022-202x.2001.01505.x"},{"key":"112972","doi-asserted-by":"crossref","unstructured":"Yan T, Xie Y, Liu Y, Shan Y, Wu X, Wang J, et al. Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. Front Immunol 2023; 14: 1194088.","DOI":"10.3389\/fimmu.2023.1194088"},{"key":"112973","unstructured":"https:\/\/doi.org.com\/10.3389\/fimmu.2023.1194088"},{"key":"112974","doi-asserted-by":"crossref","unstructured":"Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol 2018; 154: 1225\u20131226.","DOI":"10.1001\/jamadermatol.2018.2526"},{"key":"112975","unstructured":"https:\/\/doi.org.com\/10.1001\/jamadermatol.2018.2526"},{"key":"112976","doi-asserted-by":"crossref","unstructured":"Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, et al. Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther 2024; 41: 2991\u20133002.","DOI":"10.1007\/s12325-024-02810-3"},{"key":"112977","unstructured":"https:\/\/doi.org.com\/10.1007\/s12325-024-02810-3"},{"key":"112978","unstructured":"Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD [press release]. Paris and Tarrytown, NY, March 8, 2025."},{"key":"112979","doi-asserted-by":"crossref","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.","DOI":"10.1186\/2046-4053-4-1"},{"key":"112980","unstructured":"https:\/\/doi.org.com\/10.1186\/2046-4053-4-1"},{"key":"112981","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"key":"112982","doi-asserted-by":"crossref","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008\u20132012.","DOI":"10.1001\/jama.283.15.2008"},{"key":"112983","unstructured":"https:\/\/doi.org.com\/10.1001\/jama.283.15.2008"},{"key":"112984","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006\u20131012.","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"112985","unstructured":"https:\/\/doi.org.com\/10.1016\/j.jclinepi.2009.06.005"},{"key":"112986","doi-asserted-by":"crossref","unstructured":"Higgins JP, Ramsay C, Reeves BC, Deeks JJ, Shea B, Valentine JC, et al. Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Methods 2013; 4: 12\u201325.","DOI":"10.1002\/jrsm.1056"},{"key":"112987","unstructured":"https:\/\/doi.org.com\/10.1002\/jrsm.1056"},{"key":"112988","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"112989","doi-asserted-by":"crossref","unstructured":"Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479\u2013485.","DOI":"10.1016\/j.jaad.2011.06.032"},{"key":"112990","unstructured":"https:\/\/doi.org.com\/10.1016\/j.jaad.2011.06.032"},{"key":"112991","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"112992","unstructured":"https:\/\/doi.org.com\/10.1136\/bmj.i4919"},{"key":"112993","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014; 14: 135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"112994","unstructured":"https:\/\/doi.org.com\/10.1186\/1471-2288-14-135"},{"key":"112995","doi-asserted-by":"crossref","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.","DOI":"10.1186\/1471-2288-5-13"},{"key":"112996","unstructured":"https:\/\/doi.org.com\/10.1186\/1471-2288-5-13"},{"key":"112997","doi-asserted-by":"crossref","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.","DOI":"10.1186\/1745-6215-8-16"},{"key":"112998","unstructured":"https:\/\/doi.org.com\/10.1186\/1745-6215-8-16"},{"key":"112999","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177\u2013188.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"113000","unstructured":"https:\/\/doi.org.com\/10.1016\/0197-2456(86)90046-2"},{"key":"113001","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539\u20131558.","DOI":"10.1002\/sim.1186"},{"key":"113002","unstructured":"https:\/\/doi.org.com\/10.1002\/sim.1186"},{"key":"113003","doi-asserted-by":"crossref","unstructured":"Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5: 25.","DOI":"10.1186\/1472-6963-5-25"},{"key":"113004","unstructured":"https:\/\/doi.org.com\/10.1186\/1472-6963-5-25"},{"key":"113005","doi-asserted-by":"crossref","unstructured":"Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015; 350: h870.","DOI":"10.1136\/bmj.h870"},{"key":"113006","unstructured":"https:\/\/doi.org.com\/10.1136\/bmj.h870"},{"key":"113007","doi-asserted-by":"crossref","unstructured":"Yang J, Gao H, Zhang Z, Tang C, Chen Z, Wang L, et al. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Dermatol Ther 2022; 35: e15648.","DOI":"10.1111\/dth.15648"},{"key":"113008","unstructured":"https:\/\/doi.org.com\/10.1111\/dth.15648"},{"key":"113009","doi-asserted-by":"crossref","unstructured":"Qi W, Rushan X. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China. Int Immunopharmacol 2023; 118: 110050.","DOI":"10.1016\/j.intimp.2023.110050"},{"key":"113010","unstructured":"https:\/\/doi.org.com\/10.1016\/j.intimp.2023.110050"},{"key":"113011","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xu Q, Chen L, Chen J, Zhang J, Zou Y, et al. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol 2021; 12: 738907.","DOI":"10.3389\/fimmu.2021.738907"},{"key":"113012","unstructured":"https:\/\/doi.org.com\/10.3389\/fimmu.2021.738907"},{"key":"113013","doi-asserted-by":"crossref","unstructured":"Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol 2023; 125(Pt A): 111157.","DOI":"10.1016\/j.intimp.2023.111157"},{"key":"113014","unstructured":"https:\/\/doi.org.com\/10.1016\/ j.intimp.2023.111157"},{"key":"113015","doi-asserted-by":"crossref","unstructured":"Singh S, Kirtschig G, Anchan VN, Chi CC, Taghipour K, Boyle RJ, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2023; 8: CD002292.","DOI":"10.1002\/14651858.CD002292.pub4"},{"key":"113016","unstructured":"https:\/\/doi.org.com\/10.1002\/14651858.CD002292.pub4"},{"key":"113017","doi-asserted-by":"crossref","unstructured":"Liang J, Abulikemu K, Maolidan, Hu F, Zhao J, Qiu Y, et al. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review. Int Immunopharmacol 2023; 116: 109788.","DOI":"10.1016\/j.intimp.2023.109788"},{"key":"113018","unstructured":"https:\/\/doi.org.com\/10.1016\/j.intimp.2023.109788"},{"key":"113019","doi-asserted-by":"crossref","unstructured":"Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol 2020; 11: 611549.","DOI":"10.3389\/fimmu.2020.611549"},{"key":"113020","unstructured":"https:\/\/doi.org.com\/10.3389\/fimmu.2020.611549"},{"key":"113021","doi-asserted-by":"crossref","unstructured":"Abdat R, Waldman RA, de Bedout V, Czernik A, McLeod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol 2020; 83: 46\u201352.","DOI":"10.1016\/j.jaad.2020.01.089"},{"key":"113022","unstructured":"https:\/\/doi.org.com\/10.1016\/j.jaad.2020.01.089"},{"key":"113023","doi-asserted-by":"crossref","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689\u20131704.","DOI":"10.1111\/jdv.18220"},{"key":"113024","unstructured":"https:\/\/doi.org.com\/10.1111\/jdv.18220"},{"key":"113025","doi-asserted-by":"crossref","unstructured":"Ye S, Ling G, Chen M. A Systematic evaluation of dupilumab for bullous pemphigoid treatment. Dermatologic Therapy 2024; 2024: 1171779. https:\/\/doi.org\/10.1155\/2024\/1171779","DOI":"10.1155\/2024\/1171779"},{"key":"113026","doi-asserted-by":"crossref","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.","DOI":"10.3389\/fimmu.2022.928621"},{"key":"113027","unstructured":"https:\/\/doi.org.com\/10.3389\/fimmu.2022.928621"},{"key":"113028","doi-asserted-by":"crossref","unstructured":"Velin M, Dugourd PM, Sanchez A, Bahadoran P, Montaudie H, Passeron T. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids: a monocentric real-life study. J Eur Acad Dermatol Venereol 2022; 36: e539\u2013e42.","DOI":"10.1111\/jdv.17999"},{"key":"113029","unstructured":"https:\/\/doi.org.com\/10.1111\/jdv.17999"},{"key":"113030","doi-asserted-by":"crossref","unstructured":"Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study [press release]. Paris and Tarrytown, NY, Sept 11, 2024.","DOI":"10.1038\/s41572-025-00601-w"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43667\/50262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43667\/50262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:58:56Z","timestamp":1748350736000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":65,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43667","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}